Kanazawa Social Insurance Hospital

Kanazawa Social Insurance Hospital

SEARCH FILTERS
Time filter
Source Type

Watanabe H.,Nagoya University | Suzuki S.,Nagoya University | Iwata M.,Nagoya University | Iwata M.,Nihon Fukushi University | And 3 more authors.
Rigakuryoho Kagaku | Year: 2012

[Purpose] The purpose of this study was to analyze the effect of transcutaneous electrical muscle stimulation (EMS) on glucose tolerance and insulin sensitivity of normal rats. [Subjects] Male Sprague-Dawley rats were assigned to a control group, a single EMS group (1dEMS), and a 7-day EMS group (7dEMS). [Method] Bilateral rectus femoris muscles were electrically stimulated under anesthesia for 30 min/day. On day 7, an intravenous glucose tolerance test IVGTT was performed after the EMS. On day 8, an euglycemic clamp was placed 20 - 24 h after the last electrical stimulation. [Results] The glucose disappearance constant (KG) was significantly higher in the 7dEMS than in the control and 1dEMS groups. GIR (Glucose insulin resistance?) during euglycemic clamping was significantly higher in the 7dEMS than in the control group. [Conclusion] The daily application of transcutaneous EMS can improve the glucose tolerance and insulin sensitivity of normal rats. © 2012, The Society of Physical Therapy Science. All rights reserved.


Ueno S.,Kanazawa University | Mizokami A.,Kanazawa University | Fukagai T.,Showa University | Fujimoto N.,University of Occupational and Environmental Health Japan | And 12 more authors.
Anticancer Research | Year: 2013

Aim: Zoledronic acid (ZA) reduces the risk of skeletal-related events (SREs) in castration-resistant prostate cancer (CRPC) with bone metastasis and improves quality of life. It remains unclear when clinicians should initiate ZA treatment. Patients and Methods: Hormone-naïve patients were randomized to a combined androgen blockade (CAB) group or CAB with ZA group (CAB-ZA) based on Gleason score (GS) or extent of disease. The primary end-point of the study was progression-free survival (PFS) and the secondary end-point was incidence of SREs and bone pain. Results: Thirty-one and 29 patients among 60 enrolled patients were assigned to the CAB group and the CAB-ZA group, respectively. There was no significant difference in PFS between the two groups. Subgroup analyses revealed better PFS in the CAB-ZA group with GS ≥8 (p=0.021). Moreover, incidence of SREs, including bone pain, was lower in the CAB-ZA group (p=0.019). Conclusion: CABZA treatment was found to improve PFS for patients with prostate cancer with high GS. CAB-ZA treatment could be recommended for treatment of patients with prostate cancer.


Oyama K.,Kanazawa University | Fushida S.,Kanazawa University | Kaji M.,Toyama Prefectural Central Hospital | Takeda T.,Public Central Hospital of Matto Ishikawa | And 14 more authors.
Journal of Gastroenterology | Year: 2013

Background: We aimed to evaluate the efficacy of a new combination antiemetic therapy comprising aprepitant, granisetron, and dexamethasone in gastric cancer patients undergoing chemotherapy with cisplatin and S-1. Methods: Gastric cancer patients scheduled to receive their first course of chemotherapy with cisplatin (60 mg/m2) and S-1 (80 mg/m2) were treated with a new combination antiemetic therapy aprepitant, granisetron, and dexamethasone on day 1; aprepitant and dexamethasone on days 2 and 3; and dexamethasone on day 4. The patients reported vomiting, nausea, use of rescue therapy, and change in the amount of diet intake, and completed the Functional Living Index-Emesis (FLIE) questionnaire. The primary endpoint was complete response (CR; no emesis and use of no rescue antiemetics) during the overall study phase (0-120 h after cisplatin administration). The secondary endpoints included complete protection (CP; CR plus no significant nausea); change in the amount of diet intake; and the impact of chemotherapy-induced nausea and vomiting (CINV) on daily life during the overall, acute (0-24 h), and delayed (24-120 h) phases. Results: Fifty-three patients were included. CR was achieved in 88.7, 98.1, and 88.7 % of patients in the overall, acute, and delayed phases, respectively. The corresponding rates of CP were 67.9, 96.2, and 67.9 %. Approximately half of the patients had some degree of anorexia. FLIE results indicated that 79.5 % of patients reported "minimal or no impact of CINV on daily life". Conclusions: Addition of aprepitant to standard antiemetic therapy was effective in gastric cancer patients undergoing treatment with cisplatin and S-1. © 2013 Springer Japan.


Kinugasa E.,Showa University | Yumita S.,Kojinkai Central Clinic | Sato T.,Sumiyoshi Clinic Hospital | Kurosawa A.,Sumiyoshi Clinic Hospital | And 24 more authors.
Japanese Pharmacology and Therapeutics | Year: 2011

Background: This is a dose-finding, randomized, double-blind and a parallel-group study aimed to identify the appropriate starting dose of C. E. R. A., a continuous erythropoietin receptor activator, administered intravenously (i. v.) to renal anemia patients on hemodialysis. Methods: In this study, patients were treated with C. E. R. A. i. v. respectively at each of three dose levels of 25, 50 and 75 μg once every 2 weeks, after rHuEPO treatments had been finalized in patients whose Hb levels were below 9.5 g/dL (the longest wash-out period was 8 weeks). The observation period established was 16 weeks, and the primary endpoint was to analyze the slopes required to achieve the target Hb level of 12 g/dL. Results: The mean slopes of the Hb/time curves (mean (SD)) were found to be -0.027 (0.178), 0.233 (0.125) and 0.343 (0.135) g/dL/week in the 25, 50 and 75 μg of C. E. R. A. administered groups, respectively. Statistically significant increases in the slopes were found at the doses of 50 and 75 μg of C. E. R. A. i. v. compared to 25 μg of C. E. R. A. iv. The adverse events manifested were similar among the three dose groups investigated, and the antibodies against C. E. R. A. were not detected in all the patients examined. Conclusions: This study demonstrated that a dose of C. E. R. A. i. v. 50 μg once every 2 weeks was considered to be an optimal dose to be given to renal anemia patients on hemodialysis.


Hayashi T.,Ishikawa Prefectural Central Hospital | Hayashi T.,Kanazawa University | Doyama H.,Ishikawa Prefectural Central Hospital | Shirota Y.,Saiseikai Kanazawa Hospital | And 12 more authors.
PLoS ONE | Year: 2014

Objectives: Magnifying narrow-band imaging (M-NBI) is more accurate than white-light imaging for diagnosing small gastric cancers. However, it is uncertain whether moving M-NBI images have additional effects in the diagnosis of gastric cancers compared with still images. Design: A prospective multicenter cohort study. Methods: To identify the additional benefits of moving M-NBI images by comparing the diagnostic accuracy of still images only with that of both still and moving images. Still and moving M-NBI images of 40 gastric lesions were obtained by an expert endoscopist prior to this prospective multicenter cohort study. Thirty-four endoscopists from ten different Japanese institutions participated in the prospective multicenter cohort study. Each study participant was first tested using only still M-NBI images (still image test), then tested 1 month later using both still and moving M-NBI images (moving image test). The main outcome was a difference in the diagnostic accuracy of cancerous versus noncancerous lesions between the still image test and the moving image test. Results: Thirty-four endoscopists were analysed. There were no significant difference of cancerous versus noncancerous lesions between still and moving image tests in the diagnostic accuracy (59.9% versus 61.5%), sensitivity (53.4% versus 55.9%), and specificity (67.0% versus 67.6%). And there were no significant difference in the diagnostic accuracy between still and moving image tests of demarcation line (65.4% versus 65.5%), microvascular pattern (56.7% versus 56.9%), and microsurface pattern (48.1% versus 50.9%). Diagnostic accuracy showed no significant difference between the still and moving image tests in the subgroups of endoscopic findings of the lesions. Conclusions: The addition of moving M-NBI images to still M-NBI images does not improve the diagnostic accuracy for gastric lesions. It is reasonable to concentrate on taking sharp still M-NBI images during endoscopic observation and use them for diagnosis. Trial registration: Umin.ac.jp UMIN-CTR000008048 © 2014 Hayashi et al.


PubMed | Red Cross, Suzu General Hospital, Kanazawa Social Insurance Hospital, Komatsu Municipal Hospital and 7 more.
Type: Clinical Trial | Journal: PloS one | Year: 2014

Magnifying narrow-band imaging (M-NBI) is more accurate than white-light imaging for diagnosing small gastric cancers. However, it is uncertain whether moving M-NBI images have additional effects in the diagnosis of gastric cancers compared with still images.A prospective multicenter cohort study.To identify the additional benefits of moving M-NBI images by comparing the diagnostic accuracy of still images only with that of both still and moving images. Still and moving M-NBI images of 40 gastric lesions were obtained by an expert endoscopist prior to this prospective multicenter cohort study. Thirty-four endoscopists from ten different Japanese institutions participated in the prospective multicenter cohort study. Each study participant was first tested using only still M-NBI images (still image test), then tested 1 month later using both still and moving M-NBI images (moving image test). The main outcome was a difference in the diagnostic accuracy of cancerous versus noncancerous lesions between the still image test and the moving image test.Thirty-four endoscopists were analysed. There were no significant difference of cancerous versus noncancerous lesions between still and moving image tests in the diagnostic accuracy (59.9% versus 61.5%), sensitivity (53.4% versus 55.9%), and specificity (67.0% versus 67.6%). And there were no significant difference in the diagnostic accuracy between still and moving image tests of demarcation line (65.4% versus 65.5%), microvascular pattern (56.7% versus 56.9%), and microsurface pattern (48.1% versus 50.9%). Diagnostic accuracy showed no significant difference between the still and moving image tests in the subgroups of endoscopic findings of the lesions.The addition of moving M-NBI images to still M-NBI images does not improve the diagnostic accuracy for gastric lesions. It is reasonable to concentrate on taking sharp still M-NBI images during endoscopic observation and use them for diagnosis.Umin.ac.jp UMIN-CTR000008048.


Miwa K.,Ishikawa Prefectural Central Hospital | Miwa K.,Kanazawa Social Insurance Hospital | Doyama H.,Ishikawa Prefectural Central Hospital | Ito R.,Ishikawa Prefectural Central Hospital | And 12 more authors.
Gastric Cancer | Year: 2012

Background In biopsy specimens with low grade adenomas, it is often difficult to identify the presence of high grade adenomas or early carcinomas and low grade adenomas preoperatively, and clear guidelines have not yet been defined for the applicability of endoscopic treatment to low grade adenomas identified in biopsy specimens. Methods We aimed to clarify the usefulness of magnifying endoscopy with narrow band imaging (NBI) compared to conventional white light endoscopy for diagnosing actual high grade adenomas or early carcinomas with low grade adenomas, using the VS (microvascular pattern [V] and microsurface pattern [S]) classification for low grade adenomas in biopsy specimens. The study cohort consisted of 135 patients who were diagnosed with low grade adenomas in preoperative biopsy specimens and received endoscopic submucosal dissection. Results In the elevated type of lesion, magnifying endoscopy with NBI diagnosed high grade adenomas or early carcinomas at a higher sensitivity and specificity than conventional white light endoscopy (82.4 vs. 70.6%, P = 0.391, 97.3 vs. 54.7%, P < 0.0001). In the depressed macroscopic type of lesion, magnifying endoscopy with NBI also diagnosed high grade adenomas or early carcinomas at a higher sensitivity (95.5 vs. 68.2%, P = 0.0459) than conventional white light endoscopy. Although the specificity was high, at 100%, the difference when compared to conventional white light endoscopy was not significant (100 vs. 100%, P > 0.99). Conclusions For low grade adenomas in biopsy specimens, it is vital to take sufficient consideration of endoscopic findings and not take action based only on the biopsy results. If a decision is made using the VS classification with magnifying endoscopy with NBI, actual high grade adenomas or early carcinomas can be differentiated from low grade adenomas so that endoscopic treatment can be performed more strictly. © The International Gastric Cancer Association and The Japanese Gastric Cancer Association 2011.

Loading Kanazawa Social Insurance Hospital collaborators
Loading Kanazawa Social Insurance Hospital collaborators